Value of altered methylation patterns of genes RANBP3, LCP2 and GRAP2 in cfDNA in breast cancer diagnosis
Journal of Medical Biochemistry · 2024 · 43 (4) · 387-396
DOI: 10.5937/jomb0-47507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Biochemistry, 2024. Verfasst von Qin Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Zigong Maternal and Child Health Hospital, Department of Clinical Laboratory, Zigong, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The purpose of this study was to investigate the potential of plasma cfDNA methylation patterns in reflecting tumour methylation changes, focusing on three candidate sites, cg02469161, cg11528914, and cg20131654. These sites were selected for verification, with a particular emphasis on their association with breast cancer.
Methods
We conducted a comprehensive analysis of 850k whole-methylation sequencing data to identify potential markers for breast cancer detection. Subsequently, we investigated the methylation status of the genes Ran-binding protein 3 (RANBP3), Lymphocyte cytoplasmic protein 2 (LCP2), and GRB2 related adaptor protein 2 (GRAP2), situated at the specified sites, using cancer and canceradjacent tissues from 17 breast cancer patients. We also examined the methylation patterns in different molecular subtypes and pathological grades of breast cancer. Additionally, we compared the methylation levels of these genes in plasma cfDNA to their performance in tissues.
Results
Our analysis revealed that RANBP3, LCP2, and GRAP2 genes exhibited significant methylation differences between cancer and cancer-adjacent tissues. In breast cancer, these genes displayed diagnostic efficiencies of 91.0%, 90.6%, and 92.2%, respectively. Notably, RANBP3 showed a tendency towards lower methylation in HR+ breast cancer, and LCP2 methylation was correlated with tumour malignancy. Importantly, the methylation levels of these three genes in plasma cfDNA closely mirrored their tissue counterparts, with diagnostic efficiencies of 83.3%, 83.9%, and 77.6% for RANBP3, LCP2, and GRAP2, respectively.
Conclusions
Our findings propose that the genes RANBP3, LCP2, and GRAP2, located at the identified methylation sites, hold significant potential as molecular markers in blood for the supplementary diagnosis of breast cancer. This study lays the groundwork for a more in-depth investigation into the changes in gene methylation patterns in circulating free DNA (cfDNA) for the early detection not only of breast cancer but also for various other types of cancer
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zigong Maternal and Child Health Hospital, Department of Clinical Laboratory, Zigong, China.
- Zigong First People's Hospital, Department of Thyroid and Breast Surgery, Zigong, China.
Zitieren
APA
Hu, Q., Mao, Y., Lan, H., Wei, Y., Chen, Y., Ye, Q., & Che, H. (2024). Value of altered methylation patterns of genes RANBP3, LCP2 and GRAP2 in cfDNA in breast cancer diagnosis. Journal of Medical Biochemistry, 43(4), 387-396. https://doi.org/10.5937/jomb0-47507
Vancouver
Hu Q, Mao Y, Lan H, Wei Y, Chen Y, Ye Q, et al. Value of altered methylation patterns of genes RANBP3, LCP2 and GRAP2 in cfDNA in breast cancer diagnosis. Journal of Medical Biochemistry. 2024;43(4):387-396. doi:10.5937/jomb0-47507
BibTeX
@article{Hu2024,
author = {Hu, Qin and Mao, Yu and Lan, Haomiao and Wei, Yi and Chen, Yuehua and Ye, Qiang and Che, Hongying},
title = {Value of altered methylation patterns of genes RANBP3, LCP2 and GRAP2 in cfDNA in breast cancer diagnosis},
journal = {Journal of Medical Biochemistry},
year = {2024},
volume = {43},
number = {4},
pages = {387--396},
doi = {10.5937/jomb0-47507}
}
EUVIMED